Zantac Colorectal Cancer

The Federal Drug Administration (FDA) completely withdrew Zantac and other ranitidine products from the market and directed consumers to properly dispose of their remaining supplies of the popular heartburn and GERD medication in April of 2020. In doing so, it made it very clear exactly how seriously it takes the finding that Zantac – and other ranitidine products – contain the contaminate NDMA (N-Nitrosodimethylamine). One of the dangerous side effects associated with NDMA is colorectal cancer.

NDMA

All of the following national and international health organizations classify NDMA as a probable carcinogen (a cancer-causing agent):

• The World Health Organization (WHO), which positively associates NDMA with colorectal cancer
• The Environmental Protection Agency (EPA)
• The International Agency for Research on Cancer (IARC)

Colorectal Cancer

Colorectal cancer is a cancer that begins in the colon or rectum. This cancer is not only one of the most common forms of cancer but is also one of the leading causes of cancer deaths in men and women combined.

The NDMA Connection

A wide range of research connects NDMA and colorectal cancer. In an important 2014 study involving over 1,700 subjects, the association between NDMA and colorectal cancer, specifically, is established. Further, the greater the intake of NDMA, the greater the risk.

Consult with an Experienced Drug Injury Attorney Today

If you were a regular user of Zantac – or a generic equivalent – and have developed colorectal cancer, a dedicated drug injury lawyer can help. Drug companies should be held accountable for the injuries they cause, and a formidable drug injury attorney can help you do just that.